Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sterling Diagnostic Imaging boosting R&D spending after business is bought from DuPont.

This article was originally published in The Gray Sheet

Executive Summary

STERLING DIAGNOSTIC IMAGING LYNX UPGRADE will be funded by increased research and development outlays planned in the wake of the The Sterling Group's acquisition of DuPont's Diagnostic Imaging business. The larger R&D expenditures will be aimed at programs "that directly benefit our customers by anticipating and meeting their changing needs," Sterling Diagnostic Imaging President Suzanne Linderman said during an April 1 conference call. A next-generation version of the firm's Lynx electronic imaging system is one likely result of the R&D investment.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT005764

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel